Using colchicine to treat heart issues in chronic kidney disease patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness and safety of colchicine in patients suffering from chronic kidney disease. Participants aged 21 to 80 with specific kidney function metrics will receive either colchicine or a placebo. The study aims to assess how well colchicine can reduce inflammation related to uremic cardiomyopathy, a condition affecting the heart in patients with kidney disease. The trial will follow participants closely to monitor outcomes and side effects.

Why it matters

Who can join: the full rules

A. Inclusion Criteria:

* Age 21 years to 80 years (inclusive)
* eGFR of 15 to 75 mL/min per 1.73 m2
* Urine albumin-to-creatinine ratio of greater than 30 mg/g
* Use of maximally tolerated doses of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker if urine albumin-to-creatinine ratio greater than 300 mg-g
* Use of a sodium-glucose co-transporter-2 inhibitor if indicated in the opinion of the participant's primary clinician
* Willing and able to provide written informed consent and to adhere to the study protocol

B. Exclusion Criteria:

1. History of intolerance or allergy to colchicine
2. Hospitalization for any reason within the previous 30 days
3. Acute condition that requires emergent treatment in the opinion of a physician investigator
4. Stage C or D heart failure according to ACC-AHA criteria77
5. Left ventricular ejection fraction less than 40%
6. Symptomatic valvular heart disease
7. Congenital heart disease (corrected or uncorrected)
8. History of orthotopic heart transplant
9. Kidney failure, defined as kidney transplant recipient or requirement for hemodialysis or peritoneal dialysis
10. Worsening kidney function or acute kidney injury, defined as an increase in serum creatinine of greater than 0.3 mg/dL in the previous 30 days or 50% within the previous 7 days
11. Use of immunosuppressive or anti-inflammatory medications within the previous 30 days, with the exception of less than 5 days of non-steroidal anti-inflammatory drugs or corticosteroids for acute pain or other acute conditions that have since fully resolved provided that the last dose of non-steroid anti-inflammatory drug was at least 7 days before enrollment
12. Familial Mediterranean Fever, gout (unless no flare within the previous 12 months), pericarditis or other indications for colchicine treatment
13. Use of systemic antimicrobial therapy within the previous 30 days or active infection
14. History of respiratory illness that, in the opinion of a physician investigator, may increase the risk of pneumonia
15. Surgery within the previous 30 days or surgery planned to occur within the expected study period
16. Current malignancy or receipt of treatment for malignancy within the previous 1 year
17. Frailty or life-expectancy shortened by comorbidity such as cancer that would increase the participant's risk in the opinion of a physician investigator
18. Neutrophil count \< 2,000 cells/mm3
19. Platelet count \< 50,000 cells/mm3
20. Concomitant use of a P-gp inhibitor (e.g., cyclosporine, ranolazine, digoxin) and/or moderate-strong CYP3A4 inhibitor (e.g., clarithromycin, indinavir, itraconazole, ritonavir, nefazodone, diltiazem, verapamil, grapefruit juice, fluconazole)
21. Medications that may cause myopathy or rhabdomyolysis (i.e., simvastatin, gemfibrozil, fenofibrate) , a creatine kinase level after the run-in period that exceeds the upper limit of the normal laboratory reference range (if baseline was below the upper limit) or that increases by 50% or more from pre- to post-run-in
22. Moderate-severe hepatic disease (Child-Pugh B or C)
23. Pregnant or unwilling/unable to assure appropriate contraception
24. Breastfeeding

Where it's running

• Brigham and Women's Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Leo F Buckley, PharmD MPH — Brigham and Women's Hospital
• Study coordinator: Leo F Buckley, PharmD MPH
• Email: lfbuckley@bwh.harvard.edu
• Phone: 617-732-5500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Impact of TAVR on kidney function in people with aortic valve disease

  This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, RM · NCT07626710

• Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs

  This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.

  Recruiting Odense University Hospital · Odense · NCT07511283

• Oral Semaglutide for CKD and MAFLD in adults with diabetes

  This study tests whether adding oral semaglutide to standard care can slow kidney and liver disease progression in adults with CKD and MAFLD who have type 2 diabetes.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT07391267

• Eye-brain-kidney connections in chronic kidney disease

  This study will see if changes in brain network connectivity and retinal blood vessels are linked to cognitive decline and kidney function in adults with chronic kidney disease.

  Recruiting Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07358572

• Screening for chronic kidney disease

  We will see how common chronic kidney disease is among adults followed at a tertiary care center and how many cases were previously undiagnosed.

  Recruiting Institute for Clinical and Experimental Medicine · Prague · NCT07153432

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.